Valuation: Rhythm Pharmaceuticals, Inc.

Market Cap 6.35B 5.7B 5.26B 4.77B 8.91B 603B 9.02B 63.06B 25.04B 316B 23.82B 23.31B 1,002B P/E 2026 *
-31.5x
P/E 2027 * -165x
Enterprise Value 6.06B 5.44B 5.02B 4.56B 8.51B 576B 8.62B 60.22B 23.92B 302B 22.75B 22.27B 957B EV / Sales 2026 *
19.2x
EV / Sales 2027 * 10.4x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+3.03%
1 week+2.20%
Current month-3.19%
1 month-6.57%
3 months-13.14%
6 months+8.19%
Current year-13.88%
1 week 87.59
Extreme 87.59
92.72
1 month 85.38
Extreme 85.38
98.91
Current year 74.5
Extreme 74.5
119.75
1 year 74.5
Extreme 74.5
122.2
3 years 21.67
Extreme 21.67
122.2
5 years 3.04
Extreme 3.04
122.2
10 years 3.04
Extreme 3.04
122.2
Manager TitleAgeSince
Chief Executive Officer 71 2020-07-19
Chief Executive Officer 58 2020-03-27
Chief Tech/Sci/R&D Officer - 2026-08-16
Director TitleAgeSince
Director/Board Member 69 2015-03-31
Chairman 71 2017-04-10
Director/Board Member 71 2015-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Exercice

Chief Executive Officer

150,000 0.2179%
8/31/26 Exercice

Chief Financial Officer

177,148 0.2573%
8/17/26 Free

Chief Technology Officer

75,000 0.1093%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%+2.20%-17.36%+319.00% 6.35B
+0.22%-0.14%+55.12%+128.82% 1,143B
+0.91%+3.61%+41.21%+84.57% 647B
-0.12%-0.93%+25.59%+106.14% 506B
-1.48%+0.28%+50.56%+62.91% 384B
+0.86%-4.37%+61.16%+37.93% 350B
-0.19%+1.31%+30.01%+51.88% 293B
-1.09%+0.65%+2.34%+24.25% 265B
+0.75%+2.05%+53.85%+71.25% 242B
+0.25%+1.64%+32.05%+107.62% 197B
Average -0.13%+0.98%+33.45%+99.44% 403.39B
Weighted average by Cap. -0.62%+0.71%+42.67%+88.06%

Financials

2026 *2027 *
Net sales 315M 283M 261M 237M 443M 29.93B 448M 3.13B 1.24B 15.69B 1.18B 1.16B 49.75B 565M 507M 468M 425M 794M 53.67B 803M 5.61B 2.23B 28.13B 2.12B 2.08B 89.21B
Net income -204M -183M -169M -153M -286M -19.35B -290M -2.02B -804M -10.14B -765M -748M -32.16B -31.17M -27.97M -25.83M -23.42M -43.77M -2.96B -44.31M -310M -123M -1.55B -117M -114M -4.92B
Net Debt -285M -256M -237M -215M -401M -27.12B -406M -2.84B -1.13B -14.21B -1.07B -1.05B -45.07B -466M -419M -387M -351M -655M -44.31B -663M -4.63B -1.84B -23.22B -1.75B -1.71B -73.65B
Projected Income Statement - Annual - Rhythm Pharmaceuticals, Inc.
Logo Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
Employees
414
Date Price Change Volume
26-10-27 US$92.18 +3.03% 400,169
26-10-26 US$89.47 +0.22% 289,449
26-10-23 US$89.27 -1.79% 536,876
26-10-22 US$90.90 +2.57% 516,393
26-10-21 US$88.62 -1.75% 511,343
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Rhythm Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
92.18USD
Average target price
140.53USD
Spread / Average Target
+52.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rhythm Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RYTM Stock